Sign Up
Stories
Agilent's GenetiSure Dx Certification
Share
Advancements in Cancer Treatment and Mar...
Growing Markets for Pain Relief
Health & Pharma Industry Updates
ANJESO Drug Insight and Market Forecast
Biopharma Innovator GeNeuro Discloses Pr...
Diagnostics Distribution Deals Analysis ...
Overview
API
Agilent's GenetiSure Dx Postnatal Assay obtains European IVDR Class C Certification, securing its use in the EU for genetic anomaly assessment.
Ask a question
Could this certification pave the way for Agilent to expand its market reach globally?
How might this certification impact healthcare facilities and genetic testing labs in the EU?
What advancements in precision medicine could result from the increased accessibility of this assay?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage